MA30285B1 - Composes de n-formyle hydroxylamine - Google Patents

Composes de n-formyle hydroxylamine

Info

Publication number
MA30285B1
MA30285B1 MA31247A MA31247A MA30285B1 MA 30285 B1 MA30285 B1 MA 30285B1 MA 31247 A MA31247 A MA 31247A MA 31247 A MA31247 A MA 31247A MA 30285 B1 MA30285 B1 MA 30285B1
Authority
MA
Morocco
Prior art keywords
compounds
formyl hydroxylamine
hydroxylamine compounds
present
relates
Prior art date
Application number
MA31247A
Other languages
English (en)
Inventor
Kwangho Lee
Jennifer Leeds
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30285B1 publication Critical patent/MA30285B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux composés de N-formyle hydroxylamine et leurs dérivés. Lesdits composés de N-formyle hydroxylamine inhibent la peptidyl-déformylase (PDF), une enzyme présente chez les procaryotes. Ces composés servent d'antimicrobiens et d'antibiotiques. Les composés de ladite invention démontrent une inhibition sélective de la peptidyl-déformylase par rapport à d'autres métalloprotéinases telles que les MMP. L'invention porte également sur des méthodes de préparation et d'utilisation desdits composés.
MA31247A 2006-03-03 2008-09-17 Composes de n-formyle hydroxylamine MA30285B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77937706P 2006-03-03 2006-03-03

Publications (1)

Publication Number Publication Date
MA30285B1 true MA30285B1 (fr) 2009-03-02

Family

ID=38510154

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31247A MA30285B1 (fr) 2006-03-03 2008-09-17 Composes de n-formyle hydroxylamine

Country Status (19)

Country Link
US (1) US20090062537A1 (fr)
EP (1) EP1994027A2 (fr)
JP (1) JP2009529008A (fr)
KR (1) KR20080095895A (fr)
CN (1) CN101395148A (fr)
AU (1) AU2007226715A1 (fr)
BR (1) BRPI0708524A2 (fr)
CA (1) CA2643267A1 (fr)
CR (1) CR10251A (fr)
EC (1) ECSP088712A (fr)
GT (1) GT200800170A (fr)
IL (1) IL193524A0 (fr)
MA (1) MA30285B1 (fr)
MX (1) MX2008011128A (fr)
NO (1) NO20084069L (fr)
RU (1) RU2008139192A (fr)
TN (1) TNSN08344A1 (fr)
WO (1) WO2007106670A2 (fr)
ZA (1) ZA200807054B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101584694B (zh) * 2009-06-15 2011-01-12 华东师范大学 含2,5-二氢吡咯的肽脱甲酰基酶抑制剂及合成方法
CN101869563B (zh) * 2010-07-02 2011-11-16 华东师范大学 含4-亚甲基吡咯烷的肽脱甲酰基酶抑制剂
AR085698A1 (es) * 2011-03-09 2013-10-23 Glaxosmithkline Llc Inhibidores de la peptido desformilasa
CN103159660B (zh) * 2011-12-08 2016-07-06 天津市国际生物医药联合研究院 (2r)-1-(2-甲基-3-(甲氧基(甲基)氨基)-丙酰基)吡咯烷-2-羧酸及其应用
WO2013106646A2 (fr) * 2012-01-12 2013-07-18 Yale University Composés et procédés pour l'inhibition de l'ubiquitine ligase vcb e3
JP2015508414A (ja) * 2012-01-12 2015-03-19 イエール ユニバーシティ Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法
EP2817291A1 (fr) 2012-02-24 2014-12-31 F. Hoffmann-La Roche AG Composés antiviraux
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
EP3102568B1 (fr) * 2014-02-06 2018-06-27 Heptares Therapeutics Limited Composés aza bicycliques en tant qu'agonistes du récepteur muscarinique m1
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
HK1245791A1 (zh) 2015-01-20 2018-08-31 阿尔维纳斯运营股份有限公司 用於雄激素受体的靶向降解的化合物和方法
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
JP7269731B2 (ja) 2015-03-18 2023-05-09 アルビナス・オペレーションズ・インコーポレイテッド 標的タンパク質の分解向上のための化合物および方法
WO2016197114A1 (fr) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs et procédés d'utilisation associés
EP3337476A4 (fr) 2015-08-19 2019-09-04 Arvinas, Inc. Composés et procédés pour la dégradation ciblée de protéines contenant un bromodomaine
AU2016349781A1 (en) 2015-11-02 2018-05-10 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
ES2975558T3 (es) 2016-09-15 2024-07-09 Arvinas Inc Derivados de indol como degradantes de receptor de estrógeno
LT3660004T (lt) 2016-10-11 2023-06-12 Arvinas Operations, Inc. Junginiai ir metodai, skirti tikslinei androgeno receptoriaus degradacijai
EP3535265A4 (fr) 2016-11-01 2020-07-08 Arvinas, Inc. Protacs ciblant la protéine tau et méthodes d'utilisation associées
WO2018102725A1 (fr) 2016-12-01 2018-06-07 Arvinas, Inc. Dérivés de tétrahydronaphtalène et de tétrahydroisoquinoléine en tant qu'agents de dégradation des récepteurs des œstrogènes
EP3558994A4 (fr) 2016-12-23 2021-05-12 Arvinas Operations, Inc. Composés et methodes pour la dégradation ciblée de polypeptides de fibrosarcome rapidement accéléré
EP3559006A4 (fr) 2016-12-23 2021-03-03 Arvinas Operations, Inc. Composés et procédés pour la dégradation ciblée de polypeptides de kinase du foie f tal
RU2019121527A (ru) 2016-12-23 2021-01-15 Эрвинэс Оперейшнс, Инк. Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
MX2019008934A (es) 2017-01-26 2019-11-05 Arvinas Operations Inc Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,.
EP3577109A4 (fr) 2017-01-31 2020-11-18 Arvinas Operations, Inc. Ligands de céréblon et composés bifonctionnels les contenant
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
JP2021512153A (ja) 2018-01-26 2021-05-13 イエール ユニバーシティ タンパク質分解のイミド系モジュレーターおよび使用方法
US12539292B2 (en) 2018-04-01 2026-02-03 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
CN119569702A (zh) 2018-04-04 2025-03-07 阿尔维纳斯运营股份有限公司 蛋白水解调节剂及相关使用方法
US11707452B2 (en) 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
WO2021011913A1 (fr) 2019-07-17 2021-01-21 Arvinas Operations, Inc. Composés ciblant la protéine tau et procédés d'utilisation associés
ES3061133T3 (en) 2019-08-26 2026-03-31 Arvinas Operations Inc Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
US12310975B2 (en) 2019-10-17 2025-05-27 Arvinas Operations, Inc. Modulators of BCL6 proteolysis and associated methods of use
EP4077309A1 (fr) 2019-12-19 2022-10-26 Arvinas Operations, Inc. Composés et méthodes pour la dégradation ciblée du récepteur des androgènes
EP4146642A1 (fr) 2020-05-09 2023-03-15 Arvinas Operations, Inc. Procédés de fabrication d'un composé bifonctionnel, formes ultra-pures du composé bifonctionnel, et formes posologiques les comprenant
EP4204418A1 (fr) 2020-08-28 2023-07-05 Arvinas Operations, Inc. Composés de dégradation de protéine de fibrosarcome rapidement accéléré et leurs procédés d'utilisation
AU2021342287A1 (en) 2020-09-14 2023-04-13 Arvinas Operations, Inc. Crystalline forms of a compound for the targeted degradation of estrogen receptor
CA3214806A1 (fr) 2021-04-16 2022-10-20 Arvinas Operations, Inc. Modulateurs de proteolyse bcl6 et procedes d'utilisation associes
EP4584258A1 (fr) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Composés de dégradation de fibrosarcome rapidement accéléré (raf) et procédés d'utilisation associés
CN121419983A (zh) 2023-01-26 2026-01-27 阿尔维纳斯运营股份有限公司 基于小脑蛋白的kras降解protac及其相关用途
WO2025122895A1 (fr) 2023-12-08 2025-06-12 Arvinas Operations, Inc. Utilisation d'un agent de dégradation du récepteur des androgènes pour le traitement de l'amyotrophie bulbo-spinale

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036053A1 (es) * 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
BRPI0407448A (pt) * 2003-02-21 2006-01-31 Novartis Ag Processo quìmico

Also Published As

Publication number Publication date
WO2007106670A2 (fr) 2007-09-20
BRPI0708524A2 (pt) 2011-05-31
MX2008011128A (es) 2008-09-08
EP1994027A2 (fr) 2008-11-26
GT200800170A (es) 2008-10-29
RU2008139192A (ru) 2010-04-10
JP2009529008A (ja) 2009-08-13
NO20084069L (no) 2008-12-03
CA2643267A1 (fr) 2007-09-20
CR10251A (es) 2008-10-27
ECSP088712A (es) 2008-10-31
ZA200807054B (en) 2009-10-28
AU2007226715A1 (en) 2007-09-20
US20090062537A1 (en) 2009-03-05
WO2007106670A3 (fr) 2008-01-24
KR20080095895A (ko) 2008-10-29
IL193524A0 (en) 2009-08-03
TNSN08344A1 (en) 2009-12-29
CN101395148A (zh) 2009-03-25

Similar Documents

Publication Publication Date Title
WO2004033632A3 (fr) Derives d'hydantoine en tant qu'inhibiteurs de metalloproteinases matricielles et/ou de l'enzyme de conversion de tnf-alpha (tace)
EA200702470A1 (ru) Производные пиррола в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
WO2004032846A3 (fr) Derives de la triazolone et de la triazolethione, inhibiteurs des metalloproteinases de matrices et/ou de l'enzyme de conversion du tnf$g(a)
MA29393B1 (fr) Derives d'azole sous forme d'inhibiteurs de lipase et de phospholipase
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
NO20075298L (no) Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
CY1110425T1 (el) Συνεργεια των gos και της πολυφρουκτοζης
NO20071095L (no) Hittil ukjente tiofenderivater
BRPI0609121B8 (pt) 1h-benzimidazol-4-carboxamidas substituídas com um carbono quaternário na posição 2
CR10251A (es) Compuestos de n-formil-hidroxilamina
WO2005123703A8 (fr) Nouveauc derives alkynyl servant de modulateurs de recepteurs de glutamate metabotropiques
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
NO20082509L (no) Pyridopyrazinderivater og deres anvendelse
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
NO20083694L (no) Bruk av rylener som markorer for vaesker
BR0110101A (pt) N-acil-sulfonamidas promotoras de apoptose
NO20083462L (no) Nye tiofenderivater som S1P1/EDG1-reseptoragonister
MA29141B1 (fr) Pyrrolopyrazoles, servant de puissants inhibiteurs de kinases
MA30291B1 (fr) Derives de l'azolopyridin-3-one en tant qu'inhibiteurs de la lipase endotheliale
ATE244241T1 (de) Hemmung der menschlichen telomerase durch g- quadruplex interaktionverbindung
MX2007014405A (es) Novedosos derivados de oxadiazol y su uso como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.